Segal I S, Vickery R G, Walton J K, Doze V A, Maze M
Department of Anesthesia, Stanford University School of Medicine, California.
Anesthesiology. 1988 Dec;69(6):818-23. doi: 10.1097/00000542-198812000-00004.
The effect of 4(5)-[1-(2,3-dimethylphenyl)ethyl]imidazole (medetomidine), the alpha 2 adrenergic agonist, on anesthetic requirements was investigated in rats anesthetized with halothane. Halothane MAC was determined before and after either dexmedetomidine (d-enantiomer) or levomedetomidine (l-enantiomer) 10, 30, and 100 micrograms/kg or vehicle ip. There was a dose-dependent decrease in MAC with the d-, but not the l-, stereoisomer. At the highest dose of dexmedetomidine (100 micrograms/kg), halothane could be discontinued for up to 30 min with no response to tail clamping. To determine whether alpha 2 adrenoreceptors mediated this effect of dexmedetomidine on MAC, cohorts of rats were pretreated with idazoxan, 10 mg/kg ip, a highly selective alpha 2 antagonist. This completely prevented the reduction of MAC caused by dexmedetomidine. To determine whether the reduction of MAC caused by dexmedetomidine was mediated in part through either opiate or adenosine receptors, groups of rats were pretreated with either naltrexone, 5 mg/kg ip, an opiate antagonist, or 8-phenyltheophylline, 2.5 mg/kg ip, an A1 adenosine antagonist. These two pretreatments did not alter the reduction of MAC by dexmedetomidine. To determine whether postsynaptic mechanisms mediate the anesthetic effect of dexmedetomidine, rats were depleted of central catecholamine stores with either n-(2-chloroethyl)-n-ethyl-2-bromobenzylamine (DSP-4) or reserpine and alpha-methyl-para-tyrosine and MAC was determined before and after each dose of dexmedetomidine. While the catecholamine-depleted rats had a lower basal MAC than the vehicle controls, there was still a profound reduction in halothane MAC after administration of dexmedetomidine. The reduction of MAC by dexmedetomidine was blocked with idazoxan in the catecholamine depleted rats.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了α2肾上腺素能激动剂4(5)-[1-(2,3-二甲基苯基)乙基]咪唑(美托咪定)对用氟烷麻醉的大鼠麻醉需求的影响。在用10、30和100微克/千克右美托咪定(d-对映体)或左美托咪定(l-对映体)或赋形剂腹腔注射前后,测定氟烷的最低肺泡有效浓度(MAC)。d-对映体而非l-对映体使MAC呈剂量依赖性降低。在右美托咪定最高剂量(100微克/千克)时,氟烷可停用长达30分钟,对夹尾无反应。为确定α2肾上腺素受体是否介导右美托咪定对MAC的这种作用,给大鼠群体腹腔注射10毫克/千克的咪唑克生,一种高度选择性的α2拮抗剂进行预处理。这完全阻止了右美托咪定引起的MAC降低。为确定右美托咪定引起的MAC降低是否部分通过阿片或腺苷受体介导,给大鼠群体分别用5毫克/千克腹腔注射的阿片拮抗剂纳曲酮或2.5毫克/千克腹腔注射的A1腺苷拮抗剂8-苯基茶碱进行预处理。这两种预处理均未改变右美托咪定对MAC的降低作用。为确定突触后机制是否介导右美托咪定的麻醉作用,用n-(2-氯乙基)-n-乙基-2-溴苄胺(DSP-4)或利血平以及α-甲基-对-酪氨酸使大鼠中枢儿茶酚胺储备耗竭,在每次给予右美托咪定前后测定MAC。虽然儿茶酚胺耗竭的大鼠基础MAC低于赋形剂对照,但给予右美托咪定后氟烷MAC仍显著降低。在儿茶酚胺耗竭的大鼠中,咪唑克生可阻断右美托咪定对MAC的降低作用。(摘要截短于250字)